Advanced search
Publication Cover
Current Opinion on Therapeutic Patents Volume 2, 1992 - Issue 9
Journal homepage
5
Views
0
CrossRef citations to date
0
Altmetric
CNS Agents

Patent Update: Monoamine Oxidase Inhibitors

Barry G. Shearer Burroughs Wellcome Co, 3030 Cornwallis Rd Research Triangle Park, NC, 27709, USA
Pages 1421-1428 | Published online: 02 Mar 2011

References to Primary Literature

  • Zeller, EA Ueber den enzymatische Abbau von Histamin und Diaminen. Helv. Chim. Acta 1938 21 880–890.
  • Silverman, RB Hoffman, SJ Catus, WB III A mechanism for mitochondrial monoamine oxidase catalysed amine oxidation. J. Amer. Chem. Soc. 1980 102 7126–7128.
  • Cohen, G Monoamine oxidase, hydrogen peroxidase and Parkinson's disease. Adv. Neurol. 1986 45 119–129.
  • Singer, TP Von Korff, RW Murphy, DL Monoamine Oxidase: Structure, Function and Altered Functions. Academic Press New York 1979.
  • Squires, RF Additional evidence for the existence of several forms of mitochondrial monoamine oxidase in the mouse. Biochem. Pharmacol. 1968 17 1401–1409.
  • Murphy, DL Lipper, S Pickar, D Jimerson, D Cohan, RM Garrick, NA Alterman, IS Campbell, IC Selective Inhibition of Monoamine Oxidase Type A: Clinical Antidepressant Effects and Metabolic Changes in Man Monoamine Oxidase Inhibitors - State of the Art. Youdin, M, Paykel, E John Wiley & Sons New York 1981 189–205.
  • Delay, J Laine, B Buisson, JF Note on the action of isonicotnic acid hydrazine (INH) utilized in the treatment of depressive states. Ann. Med. Psychol. 1952 2 689–692.
  • Kline, NS Therapy with psychic energizers A Pharmacological Approach to the Study of the Mind. Feathersone, RM, Simon, A Thomas Springfield 1959 295–322.
  • Gilman, AG Goodman, LS Gilman, A The Pharmacological Basis of Therapeutics 6th ed. Macmillan New York 1980 427.
  • Blackwell, B Marley, E Price, J Taylor, D Interaction with cheese and its constituents with monoamine oxidase inhibitors. Brit. J. Psychiat. 1967 113 349–365.
  • Meszaros, LA The biochemistry of stress. CHEMTECH 1988 18 22–25.
  • Strolin, BM Dostert, P Overview of the present state of MAO inhibitors. J. Neural. Transm. 1987 23 103–119 (Suppl)
  • White, HL Harfenist, M Beek, O Soroko, F Cooper, BR Maxwell, RA BW A616U- a selective inhibitor of MAO-A with negligible tyramine-potentiating activity and potential antidepressant activity. Soc. Neurosci. Abstr. 1985 11 4442.
  • Harfenist, M McGee, DP White, HL A selective, reversible competitive inhibitor of monoamine oxidase A containing no nitrogen, with negligible potentiation of tyramine-induced blood pressure rise. J. Med. Chem. 1991 34 2931–2933.
  • Cooper, BR White, HL Norton, RM Rigdon, GC Howard, JL Kraemer, GW Ferris, RM Overview of the CNS pharmacology of BW 1370U87: A chemically novel, reversible, selective MAO-A inhibitor with potential to be a new antidepressant drug. Drug Dev. Res. 1992 25 181–190.
  • Stabl, M Biziere, K Schmid-Burgk, W Amrein, R Review of comparative clinical trials. Moclobemide vs tricylic antidepressants and vs placebo in depressive states. J. Neural. Transm. 1989 28 77–89 (Suppl)
  • DaPrada, M Kettler, R Keller, HH Cesura, AM Richards, JB Saura Marti, J Muggli-Maniglio, D Kyburz, E Imhof, R From moclobemide to Ro 19–6327 and Ro-41–1049: The development of a new class of reversible, selective MAO-A and MAO-B inhibitors. J. Neural. Transm. 1990 29 279–292 (Suppl)
  • Rando, RR Eigner, A The pseudoirreversible inhibition of monoamine oxidase by allylamine. Mol. Pharmacol. 1977 13 1005–1013 For other examples of MAO inhibiting allylamines see:; and Rando RR: 3-Bromoallylamine induced irreversible inhibition of monoamine oxidase. J. Amer. Chem. Soc. (1973) 95: 4438–4439.
  • McDonald, IA Lacoste, JM Bey, P Palfreyman, MG Zreika, M Enzyme-activated irreversible inhibitors of monoamine oxidase: Phenylallylamine structure-activity relationships. J. Med. Chem. 1985 28 186–193.
  • Kyburz, E New developments in the field of MAO inhibitors. Drug News Perspect. 1990 3 592–599.
  • Schiwy, W Hearh, WR Delini-Stula, A Therapeutic and side effect profile of a selective and reversible MAO-A inhibitor, brofaramine. J. Neural. Transm. 1989 28 33–34 (Suppl)
  • Moller, HJ Wendt, G Waldmeier, P Brofaramine- A selective, reversible, and short-acting MAO-A inhibitor: Review of the pharmacological and clinical findings. Pharmacopsychiat. 1991 24 50–54.
  • Norman, TR Burrows, GD Monoamine oxidase, monoamine oxidase inhibitors, and panic disorder. J. Neural. Transm. 1989 28 53–63 (Suppl)
  • Rudorfer, MV Potter, WZ Antidepressants: A comparative review of the clinical pharmacology and therapeutic use of the 'newer' versus 'older' drugs. Drugs 1989 37 713–738.
  • Cohen, G Spina, MB Deprenyl suppresses the oxidant stress associated with increased dopamine turnover. Ann. Neurol. 1989 26 689–690.
  • Tariot, PN Sunderland, T Weingartner, H Murphy, DL Welkowitz, JA Thompson, K Cohen, RM Cognitive effects of L-deprenyl in Alzheimer's disease. Psychopharmacology 1987 91 489–495.

References to Patent literature

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.